4 hrs ago | Drugs.com
Novartis Increases Staff Pay by 1.5% from April 2010
From M2 Europharma 20 November 2009 - Swiss drug maker Novartis AG said Friday it will raise the payments of its employees in Basel and in the plants in the Rheine valley by an average of 1.5% as of April 2010.
Opening ceremony for Novartis facility Nov. 24
The opening ceremony for the first large-scale US Flu Cell Culture and adjuvant manufacturing facility, developed in partnership with the U.S. Department of Health and Human Services, will be held Tues.
Deal Economy 2010: Novartis' Sullivan on cross-border deals
Marvelle Sullivan, the head of corporate legal M&A at Novartis AG , spoke at The Deal Economy 2010 conference on Wednesday in New York City.
Flu Shot Made From Caterpillars May Win Pivotal Backing of U.S. Advisers
Protein Sciences Corp. may win backing from a U.S. panel today for a flu vaccine that can be produced in a third of the time it takes Sanofi-Aventis SA , GlaxoSmithKline Plc and Novartis AG to make their shots.
Pfizer reportedly to sell generic drugs in Japan
Pfizer Inc. plans to release generic drugs in Japan as early as 2011, expecting demand to increase as industrialized nations intensify efforts to control drug prices, according to a report Thursday.
Four Healthcare Stocks On Fire
A fair amount of uncertainty continues to surround the healthcare sector as Congress debates how it can improve the existing system in the U.S. , but that has not prevented a number of stocks in the space from storming up the charts.
Novartis unveils Prevacid24HR Over-the-Counter in US for frequent heartburn treatment
Healthcare solutions provider Novartis declared on Thursday the launch of Prevacid24HR over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.
Novartis to Ship 30 Million Vaccine Doses
Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.
How Do You Say 'Drug Development' in Mandarin?
I've been critical of pharma's claims that developing countries are going to save them from the inevitable patent cliffs.
Analyst Report ) recently received approval from the U.S. Food and Drug Administration for its unadjuvanted influenza A pandemic vaccine.
Novartis Says Weak IP Protection Makes India R&D Impossible
Novartis once again said that India is not a place to do R&D because its IP laws are not strong enough to protect discoveries.
The Life-and-Death Situation That Isn't
"This is literally a life-and-death issue that must be handled with great care." -- Celgene spokesman Brian Gill, as quoted in The Wall Street Journal .
Video: Novartis Launches Prevacid(R)24HR Over-the-Counter for Full...
Novartis announced the availability of PrevacidA 24HR over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.
Swiss left unimpressed by swine flu policy
Government calls for at-risk individuals to get vaccinated against H1N1 have fallen largely on deaf Swiss ears, with many believing the threat is exaggerated.
Novartis Corporation to Acquire Majority Stake in Hard To Treat...
SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.
Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Human Genome Sciences .
Winners & Losers in Fight Against the Flu
For most of us, the very mention of "swine flu" brings about feelings of fear, or at the very least thoughts of fevers, congestion, annoying coughs and stuffy noses.
Novartis Receives Regulatory Approval In Germany For Celtura , A Cell ...
Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A 2009 monovalent vaccine, Celtura.
Novartis to invest $1 billion in China R&D institute
Novartis plans to invest $1 billion during the next 5 years to increase R&D activities in China, including a significant expansion of The Novartis Institute of BioMedical Research in Shanghai.
HSBC, Roche, Novartis Under Probe in Korea Over Large-Scale Tamiflu Sales
Roche Holdings AG , maker of the Tamiflu antiviral treatment, is under investigation in South Korea for its alleged involvement in illegal sales of the drug as the number of swine flu cases jumped.
Also on Topix